The gut microbiota in neurodegenerative diseases: revisiting possible therapeutic targets for cannabidiol
Understanding the pathophysiology of Alzheimer's disease (AD) is essential to improve the efficacy of treatments and, consequently, patients' lives. Unfortunately, traditional therapeutic strategies have not been effective. There is therefore an urgent need to discover or develop alternati...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-12-01
|
| Series: | Heliyon |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2405844022034600 |
| _version_ | 1828071306050928640 |
|---|---|
| author | Bruna Stefane Alves de Oliveira Debora Sandrini Milanezi Priscila do Val Gonzaga Fernanda Rabello Detoni Renato Nery Soriano |
| author_facet | Bruna Stefane Alves de Oliveira Debora Sandrini Milanezi Priscila do Val Gonzaga Fernanda Rabello Detoni Renato Nery Soriano |
| author_sort | Bruna Stefane Alves de Oliveira |
| collection | DOAJ |
| description | Understanding the pathophysiology of Alzheimer's disease (AD) is essential to improve the efficacy of treatments and, consequently, patients' lives. Unfortunately, traditional therapeutic strategies have not been effective. There is therefore an urgent need to discover or develop alternative treatment strategies. Recently, some pieces of the puzzle appear to emerge: on a hand, the gut microbiota (GM) has gained attention since intestinal dysbiosis aggravates and generates some of the pathological processes of AD; on the other hand, cannabidiol (CBD), a phytocannabinoid, attenuates intestinal inflammation and possesses neuroprotective properties. Intestinal dysbiosis (increased population of proinflammatory bacteria) in AD increases plasma lipopolysaccharide and Aβ peptide levels, both responsible for increasing the permeability of the blood-brain barrier (BBB). A leaky BBB may facilitate the entry of peripheral inflammatory mediators into the central nervous system and ultimately aggravate neuroinflammation and neuronal death due to chronic activation of glial cells. Studies investigating the GM reported a strong relationship between intestinal dysbiosis and AD. In this review we conjecture that the GM is a promising therapeutic target for CBD in the context of AD. |
| first_indexed | 2024-04-11T00:51:24Z |
| format | Article |
| id | doaj.art-99cb48f69c0a42419f651c51fdade509 |
| institution | Directory Open Access Journal |
| issn | 2405-8440 |
| language | English |
| last_indexed | 2024-04-11T00:51:24Z |
| publishDate | 2022-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Heliyon |
| spelling | doaj.art-99cb48f69c0a42419f651c51fdade5092023-01-05T08:39:11ZengElsevierHeliyon2405-84402022-12-01812e12172The gut microbiota in neurodegenerative diseases: revisiting possible therapeutic targets for cannabidiolBruna Stefane Alves de Oliveira0Debora Sandrini Milanezi1Priscila do Val Gonzaga2Fernanda Rabello Detoni3Renato Nery Soriano4Department of Medicine, Federal University of Juiz de Fora, Governador Valadares, MG, 35032-620, BrazilDepartment of Medicine, Federal University of Juiz de Fora, Governador Valadares, MG, 35032-620, BrazilDepartment of Medicine, Federal University of Juiz de Fora, Governador Valadares, MG, 35032-620, BrazilDepartment of Medicine, Federal University of Juiz de Fora, Governador Valadares, MG, 35032-620, BrazilDivision of Physiology and Biophysics, Department of Basic Life Sciences, Federal University of Juiz de Fora, Governador Valadares, MG, 35020-360, Brazil; Corresponding author.Understanding the pathophysiology of Alzheimer's disease (AD) is essential to improve the efficacy of treatments and, consequently, patients' lives. Unfortunately, traditional therapeutic strategies have not been effective. There is therefore an urgent need to discover or develop alternative treatment strategies. Recently, some pieces of the puzzle appear to emerge: on a hand, the gut microbiota (GM) has gained attention since intestinal dysbiosis aggravates and generates some of the pathological processes of AD; on the other hand, cannabidiol (CBD), a phytocannabinoid, attenuates intestinal inflammation and possesses neuroprotective properties. Intestinal dysbiosis (increased population of proinflammatory bacteria) in AD increases plasma lipopolysaccharide and Aβ peptide levels, both responsible for increasing the permeability of the blood-brain barrier (BBB). A leaky BBB may facilitate the entry of peripheral inflammatory mediators into the central nervous system and ultimately aggravate neuroinflammation and neuronal death due to chronic activation of glial cells. Studies investigating the GM reported a strong relationship between intestinal dysbiosis and AD. In this review we conjecture that the GM is a promising therapeutic target for CBD in the context of AD.http://www.sciencedirect.com/science/article/pii/S2405844022034600Intestinal dysbiosisAlzheimer's diseaseBlood-brain barrierCannabis sativaMicrobiota-gut-brain axis |
| spellingShingle | Bruna Stefane Alves de Oliveira Debora Sandrini Milanezi Priscila do Val Gonzaga Fernanda Rabello Detoni Renato Nery Soriano The gut microbiota in neurodegenerative diseases: revisiting possible therapeutic targets for cannabidiol Heliyon Intestinal dysbiosis Alzheimer's disease Blood-brain barrier Cannabis sativa Microbiota-gut-brain axis |
| title | The gut microbiota in neurodegenerative diseases: revisiting possible therapeutic targets for cannabidiol |
| title_full | The gut microbiota in neurodegenerative diseases: revisiting possible therapeutic targets for cannabidiol |
| title_fullStr | The gut microbiota in neurodegenerative diseases: revisiting possible therapeutic targets for cannabidiol |
| title_full_unstemmed | The gut microbiota in neurodegenerative diseases: revisiting possible therapeutic targets for cannabidiol |
| title_short | The gut microbiota in neurodegenerative diseases: revisiting possible therapeutic targets for cannabidiol |
| title_sort | gut microbiota in neurodegenerative diseases revisiting possible therapeutic targets for cannabidiol |
| topic | Intestinal dysbiosis Alzheimer's disease Blood-brain barrier Cannabis sativa Microbiota-gut-brain axis |
| url | http://www.sciencedirect.com/science/article/pii/S2405844022034600 |
| work_keys_str_mv | AT brunastefanealvesdeoliveira thegutmicrobiotainneurodegenerativediseasesrevisitingpossibletherapeutictargetsforcannabidiol AT deborasandrinimilanezi thegutmicrobiotainneurodegenerativediseasesrevisitingpossibletherapeutictargetsforcannabidiol AT prisciladovalgonzaga thegutmicrobiotainneurodegenerativediseasesrevisitingpossibletherapeutictargetsforcannabidiol AT fernandarabellodetoni thegutmicrobiotainneurodegenerativediseasesrevisitingpossibletherapeutictargetsforcannabidiol AT renatonerysoriano thegutmicrobiotainneurodegenerativediseasesrevisitingpossibletherapeutictargetsforcannabidiol AT brunastefanealvesdeoliveira gutmicrobiotainneurodegenerativediseasesrevisitingpossibletherapeutictargetsforcannabidiol AT deborasandrinimilanezi gutmicrobiotainneurodegenerativediseasesrevisitingpossibletherapeutictargetsforcannabidiol AT prisciladovalgonzaga gutmicrobiotainneurodegenerativediseasesrevisitingpossibletherapeutictargetsforcannabidiol AT fernandarabellodetoni gutmicrobiotainneurodegenerativediseasesrevisitingpossibletherapeutictargetsforcannabidiol AT renatonerysoriano gutmicrobiotainneurodegenerativediseasesrevisitingpossibletherapeutictargetsforcannabidiol |